奥希替尼联合贝伐珠单抗一线治疗EGFR T790M突变晚期NSCLC患者的有效性和安全性  

Observation of Efficacy and Safety of Ositinib Plus Bevacizumab in First-line Treatment of Patients with Advanced NSCLC with EGFR T790M Mutation

作　　者：张丹丹[1] 杨翠翠 刘彩虹[1] 李桂芳 ZHANG Dandan;YANG Cuicui;LIU Caihong(The First Affiliated Hospital of Henan University of Science and Technology,Luoyang,471002)

机构地区：[1]河南科技大学第一附属医院,471002

出　　处：《实用癌症杂志》2024年第3期443-446,共4页The Practical Journal of Cancer

基　　金：2020年河南省医学科技攻关计划联合共建项目(编号:LHGJ20200571)。

摘　　要：目的探究奥希替尼联合贝伐珠单抗治疗EGFRT 790M突变晚期非小细胞型肺癌(NSCLC)患者的有效性和安全性。方法选取82例EGFR T790M突变晚期NSCLC患者,按单双号分2组。对照组41例采用奥希替尼治疗,研究组41例采用奥希替尼联合贝伐珠单抗治疗。经过4个周期的治疗,对2组治疗的有效性和安全性进行评估。结果治疗后研究组客观缓解率(ORR)、疾病控制率(DCR)和T淋巴细胞亚群(CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+))水平均高于对照组(P<0.05),研究组癌胚抗原(CEA)、人细胞角蛋白21-1(cyfra21-1)、糖类抗原CA125(CA125)水平低于对照组(P<0.05)。2组贫血、皮疹、肝功能损伤、胃肠道反应、蛋白尿和高血压等不良反应分级为1~2级,差异不显著(P>0.05)。结论奥希替尼联合贝伐珠单抗一线治疗EGFR T790M突变晚期NSCLC,可改善患者免疫功能,降低肿瘤标志物水平,临床疗效高,安全性佳。Objective To investigate the efficacy and safety of osimertinib combined with bevacizumab in patients with EGFRT 790M mutated advanced non-small cell lung cancer(NSCLC).Methods A total of 82 patients with EGFR T790M mutation advanced NSCLC were selected and divided into 2 groups according to odd and even number.41 patients in the control group were treated with osimertinib and 41 patients in the study group were treated with osimertinib combined with bevacizumab.After 4 cycles of treatment,the efficacy and safety of the 2 groups were evaluated.Results After treatment,the objective remission rate(ORR),disease control rate(DCR)and T lymphocyte subsets(CD3^(+),CD4^(+),CD4^(+)/CD8^(+))levels in the study group were higher than those in the control group(P<0.05).The levels of carcinoembryonic antigen(CEA),human cytokeratin 21-1(cyfra21-1)and carbohydrate antigen CA125(CA125)in the study group were lower than those in the control group(P<0.05).The adverse reactions such as anemia,rash,liver function damage,gastrointestinal reactions,proteinuria and hypertension in the 2 groups were graded as 1-2,and the difference was not statistically significant(P>0.05).Conclusion Osimertinib combined with bevacizumab as first-line treatment for advanced NSCLC with EGFR T790M mutation can improve the immune function of patients,reduce the level of tumor markers,with high clinical efficacy and good safety.

关 键 词：奥希替尼 贝伐珠单抗 EGFR T790M突变 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]